Free Trial
NASDAQ:XTLB

XTL Biopharmaceuticals 5/13/2024 Earnings Report

XTL Biopharmaceuticals EPS Results

Actual EPS
$0.10
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

XTL Biopharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

XTL Biopharmaceuticals Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

XTL Biopharmaceuticals Earnings Headlines

XTL Biopharmaceuticals names Noam Band as CEO
Trump’s Manhattan Project
The President’s tour of the Middle East… the deal for Ukraine’s mineral rights… Elon’s strange time in Washington… even Trump’s obsession with seizing Greenland. There’s a singular force that connects the dots… And it could threaten to transform American life – and your wealth – forever.
See More XTL Biopharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like XTL Biopharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on XTL Biopharmaceuticals and other key companies, straight to your email.

About XTL Biopharmaceuticals

XTL Biopharmaceuticals (NASDAQ:XTLB) engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.

View XTL Biopharmaceuticals Profile

More Earnings Resources from MarketBeat